Our cutting-edge technology and advanced facilities ensure controlled success throughout our processes
GLP-1 weight-loss drugs will still be cheap with Medicare, but there's a catch Medicare has delayed a program for older Americans that would've required participating insurance companies to cover GLP-1 weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Your provider may suggest checking your blood pressure at home with a digital cuff
Semaglutide Weekly Injection Active Ingredient in Ozempic and Wegovy 15% Body Weight Reduction GLP-1 Receptor Agonist FDA Approved for Type 2 Diabetes (2017) and Weight Loss (2021) Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain Tirzepatide Weekly Injection Active Ingredient in Mounjaro 20% Body Weight reduction Dual GLP-1 and GIP Receptor Agonist FDA Approved for Type 2 Diabetes (2022) and on Fast-track for Weight Loss Approval in 2023 Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain These injections are GLP-1 medications that have been FDA-approved for Type 2 diabetes because of their ability to lower blood sugar and raise insulin levels